SM
ITCI

SG3 Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

SG3 Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-27,180
Closed -$864K – 1530
2020
Q4 		$864K Buy
+27,180
New +$714K 0.02% 601
2020
Q3 		– Sell
-35,000
Closed -$898K – 1103
2020
Q2 		$898K Buy
+35,000
New +$709K 0.06% 305

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

SG3 Management's ITCI Position: Q1 2021 in Review

SG3 Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2021, closing a stake of 27,180 shares — an estimated $864K sold.

SG3 Management first reported a position in ITCI in Q2 2020 and held it in 2 quarters. The position peaked at $898K in Q2 2020. 170 funds tracked by Wall St. Rank hold ITCI as of Q1 2021.

  • SG3 Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2021 after selling out during the quarter.
  • SG3 Management sold 27,180 Intra-Cellular Therapies Inc. shares in Q1 2021, an estimated $864K.
  • SG3 Management first reported a position in Intra-Cellular Therapies Inc. in Q2 2020 and held it in 2 quarters.
  • SG3 Management's Intra-Cellular Therapies Inc. position peaked at $898K in Q2 2020.
  • 170 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2021.

Based on SG3 Management's 13F filing for Q1 2021, filed 17 May 2021.